Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.

Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion an...

Full description

Bibliographic Details
Main Authors: Jose A Santiago, Clemens R Scherzer, Judith A Potashkin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4184821?pdf=render
id doaj-07796666640548fda25780f46c93313b
record_format Article
spelling doaj-07796666640548fda25780f46c93313b2020-11-24T22:03:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e10904210.1371/journal.pone.0109042Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.Jose A SantiagoClemens R ScherzerJudith A PotashkinIncreasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson's disease (PROBE). The results from this study reinforce the idea that shared molecular networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted.http://europepmc.org/articles/PMC4184821?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Jose A Santiago
Clemens R Scherzer
Judith A Potashkin
spellingShingle Jose A Santiago
Clemens R Scherzer
Judith A Potashkin
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
PLoS ONE
author_facet Jose A Santiago
Clemens R Scherzer
Judith A Potashkin
author_sort Jose A Santiago
title Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
title_short Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
title_full Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
title_fullStr Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
title_full_unstemmed Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
title_sort network analysis identifies sod2 mrna as a potential biomarker for parkinson's disease.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2014-01-01
description Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson's disease (PROBE). The results from this study reinforce the idea that shared molecular networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted.
url http://europepmc.org/articles/PMC4184821?pdf=render
work_keys_str_mv AT joseasantiago networkanalysisidentifiessod2mrnaasapotentialbiomarkerforparkinsonsdisease
AT clemensrscherzer networkanalysisidentifiessod2mrnaasapotentialbiomarkerforparkinsonsdisease
AT judithapotashkin networkanalysisidentifiessod2mrnaasapotentialbiomarkerforparkinsonsdisease
_version_ 1725831955142934528